Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
RGEN Repligen Corp
- Stocks
- Healthcare
- NASDAQ: RGEN
Price (delayed)
$124.02
Market cap
$6.97B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.42
Enterprise value
$6.95B
Repligen is an American company devoted to the development and production of materials used in the manufacture of biological drugs. The company is based in Waltham, Massachusetts, and incorporated in
Highlights
The debt has contracted by 7% YoY
RGEN's gross profit is up by 6% YoY and by 5% QoQ
The company's net income has shrunk by 198% YoY but it rose by 10% QoQ
RGEN's EPS has dropped by 198% year-on-year but it is up by 9% since the previous quarter
Key stats
What are the main financial stats of RGEN
Market
Valuations
Earnings
Shares outstanding
56.18M
Market cap
$6.97B
Enterprise value
$6.95B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.51
Price to sales (P/S)
10.7
EV/EBIT
N/A
EV/EBITDA
80.29
EV/Sales
10.69
Revenue
$650.43M
Gross profit
$288.61M
Operating income
-$32.29M
Net income
-$22.98M
EBIT
-$1.84M
EBITDA
$86.61M
Free cash flow
$116.77M
Per share
Balance sheet
Liquidity
EPS
-$0.42
EPS diluted
-$0.42
Free cash flow per share
$2.08
Book value per share
$35.36
Revenue per share
$11.59
TBVPS
$24.24
Total assets
$2.85B
Total liabilities
$866.66M
Debt
$683.7M
Equity
$1.99B
Working capital
$880.47M
Debt to equity
0.34
Current ratio
6.79
Quick ratio
5.56
Net debt/EBITDA
-0.16
Margins
Efficiency
Dividend
EBITDA margin
13.3%
Gross margin
44.4%
Net margin
-3.5%
Operating margin
-5%
Return on assets
-0.8%
Return on equity
-1.2%
Return on invested capital
-0.1%
Return on capital employed
-0.1%
Return on sales
-0.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RGEN stock price
How has the Repligen stock price performed over time
Intraday
0.54%
1 week
5.51%
1 month
4.97%
1 year
0.71%
YTD
-13.84%
QTD
-2.53%
Financial performance
How have Repligen's revenue and profit performed over time
Revenue
$650.43M
Gross profit
$288.61M
Operating income
-$32.29M
Net income
-$22.98M
Gross margin
44.4%
Net margin
-3.5%
The company's net income has shrunk by 198% YoY but it rose by 10% QoQ
The net margin has plunged by 192% YoY but it has grown by 13% from the previous quarter
The operating income has plunged by 186% YoY but it has increased by 8% from the previous quarter
The operating margin has plunged by 182% YoY but it has grown by 9% from the previous quarter
Price vs fundamentals
How does RGEN's price correlate with its fundamentals
Growth
What is Repligen's growth rate over time
Valuation
What is Repligen stock price valuation
P/E
N/A
P/B
3.51
P/S
10.7
EV/EBIT
N/A
EV/EBITDA
80.29
EV/Sales
10.69
RGEN's EPS has dropped by 198% year-on-year but it is up by 9% since the previous quarter
The P/B is 37% less than the 5-year quarterly average of 5.6 and 8% less than the last 4 quarters average of 3.8
RGEN's P/S is 36% below its 5-year quarterly average of 16.8 and 12% below its last 4 quarters average of 12.1
The revenue has grown by 4.9% YoY and by 2.5% from the previous quarter
Efficiency
How efficient is Repligen business performance
The return on equity has dropped by 200% year-on-year but it rose by 8% since the previous quarter
RGEN's ROA has dropped by 189% year-on-year but it is up by 11% since the previous quarter
RGEN's return on sales has dropped by 104% year-on-year but it has surged by 70% since the previous quarter
The ROIC has plunged by 102% YoY but it has soared by 80% from the previous quarter
Dividends
What is RGEN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RGEN.
Financial health
How did Repligen financials performed over time
RGEN's quick ratio is down by 21% since the previous quarter but it is up by 13% year-on-year
Repligen's current ratio has decreased by 19% QoQ but it has increased by 9% YoY
The debt is 66% less than the equity
Repligen's debt to equity has decreased by 11% YoY and by 2.9% from the previous quarter
The debt has contracted by 7% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.